STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink tumors and reduce radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults up to age 21 with newly diagnosed nasopharyngeal carcinoma. The goal is to see if thi…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
Immunotherapy duo aims to stall return of rare throat cancer
Disease control Recruiting nowThis study is for people with a type of throat cancer (nasopharyngeal carcinoma) that has come back or spread. After initial chemotherapy and immunotherapy, participants receive either the standard immunotherapy (nivolumab) alone or combined with another drug (relatlimab) to see …
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:00 UTC
-
New hope for Tough-to-Treat throat cancer: drug cocktail shows promise
Disease control Recruiting nowThis study tests whether adding a targeted drug (cabozantinib) to a two-drug immunotherapy (nivolumab and ipilimumab) can help shrink or stabilize advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer progressed after platinum chemotherapy and i…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a personalized vaccine made from a patient's own tumor cells, alone or with the immunotherapy drug pembrolizumab, for head and neck cancer that has returned or spread. The goal is to find the safest dose and see if the vaccine helps the immune system …
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding the cholesterol-lowering drug lovastatin to the immunotherapy pembrolizumab can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS≥1) will receive both drugs.…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Can blood tests predict who will do their swallowing exercises?
Knowledge-focused Recruiting nowThis study looks at why people with head and neck cancer do or don't follow swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the illness affect exercise habits. The goal is to learn what h…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC